Publications by authors named "Steven Fruchtman"

Claim this Profile
C
CETSA-MS unveils novel targets engaged by rigosertib to promote anti-tumor activity and inflammatory responses.
Petros Kechagioglou, Hajime Yurugi, Camille Dupont, Alexey Chernobrovkin, Rossana Romero, Steven M Fruchtman

iScience· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Shyamala C Navada, Guillermo Garcia-Manero, Rosalie OdchimarReissig, Naveen Pemmaraju, Yesid Alvarado, Steven M Fruchtman

Leuk Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Katherine A Rauen, Lisa Schoyer, Lisa Schill, Beth Stronach, John Albeck, Steven M Fruchtman

Am J Med Genet A· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Shyamala C Navada, Steven M Fruchtman, Rosalie Odchimar-Reissig, Erin P Demakos, Michael E Petrone

Leuk Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Aziz Nazha, Mikkael A Sekeres, Rami Komrokji, David P Steensma, Hagop Kantarjian, Steven M Fruchtman

Blood Cancer J· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Christopher R Cogle, Sandra E Kurtin, Tanya G K Bentley, Michael S Broder, Eunice Chang, Steven Fruchtman

Oncologist· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of polycythemia vera with imatinib mesylate.
Richard T Silver, Michael H Bourla, Katherine Vandris, Steven Fruchtman, Jerry L Spivak

Leuk Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia.
Vesna Najfeld, Joseph Tripodi, Angela Scalise, Lewis R Silverman, Richard T Silver, Steven Fruchtman

Br J Haematol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
Windy Berkofsky-Fessler, Monica Buzzai, Marianne K-H Kim, Steven Fruchtman, Vesna Najfeld

Clin Cancer Res· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases.
Mingjiang Xu, Edward Bruno, Joseph Chao, Stephen Huang, Guido Finazzi, Steven M Fruchtman

Blood· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.
Damiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, Josef T Prchal, Uday Popat, Steven Fruchtman

Blood· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Steven M Fruchtman, Robert M Petitt, Harriet S Gilbert, Garrick Fiddler, Andrew Lyne

Leuk Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.
Mingjiang Xu, Edward Bruno, Joseph Chao, Hongyu Ni, Valerie Lindgren, Steven M Fruchtman

Blood· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The successful treatment of severe aplastic anemia with autologous cord blood transplantation.
Steven M Fruchtman, Anne Hurlet, Robert Dracker, Luis Isola, Benjamin Goldman

Biol Blood Marrow Transplant· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for megakaryocyte engraftment following reduced-intensity conditioning.
Deborah L French, Steven Fruchtman, W Beau Mitchell, Barry S Coller, Hava Peretz

Exp Hematol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment paradigms in the management of myeloproliferative disorders.
Steven M Fruchtman

Semin Hematol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Celia Grosskreutz, Virginia Ross, Eileen Scigliano, Steven Fruchtman, Luis Isola

Biol Blood Marrow Transplant· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem cell transplantation.
Steven Fruchtman

Mt Sinai J Med· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera: implications for its role in diagnosis and pathogenesis.
Vesna Najfeld, Shai Fuchs, Paul Merando, Kimberly Lezon-Geyda, Steven Fruchtman

Exp Hematol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approaches to the treatment of thrombocytosis.
Steven Fruchtman

Clin Adv Hematol Oncol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transplant decision-making strategies in the myeloproliferative disorders.
Steven M Fruchtman

Semin Hematol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected.
Vesna Najfeld, Lya Montella, Angela Scalise, Steven Fruchtman

Br J Haematol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Syngeneic stem cell transplant for spent-phase polycythaemia vera: eradication of myelofibrosis and restoration of normal haematopoiesis.
Shambavi Richard, Luis Isola, Eileen Scigliano, Harvinder Singh, Vesna Najfeld, Steven Fruchtman

Br J Haematol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis